Phaseline

Targets › PIK3R1

PIK3R1 (Phosphatidylinositol 3-kinase regulatory subunit alpha): drug programs, companies and trials

5 programs from 5 companies in 18 trials: 9 Phase 2, 7 Phase 1, 2 Phase 3; Oncology, Infectious disease, Other; next expected readout Dec 2026.

Binds to activated (phosphorylated) protein-Tyr kinases, through its SH2 domain, and acts as an adapter, mediating the association of the p110 catalytic unit to the plasma membrane. Necessary for the insulin-stimulated increase in glucose uptake and glycogen synthesis in insulin-sensitive tissues. (UniProt, P27986)

Open in Phaseline: the race on PIK3R1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
CelcuityGedatolisib
Serine/threonine-protein kinase mTOR inhibitor; PI3-kinase class I inhibitor
MTOR, PIK3R1, PIK3CB, PIK3CG, PIK3CAPhase 3Breast Cancer; mCRPC (Metastatic Castration-resistant Prostate Cancer); Endometrial Cancer; TNBC - Triple-Negative Breast CancerDec 2026
National Cancer Institute (NCI)Taselisib (GDC-0032)
PI3-kinase class I inhibitor
PIK3R1, PIK3CB, PIK3CG, PIK3CA, PIK3R2Phase 2Advanced LymphomaMar 2027
RestorbioDactolisib (BEZ235)
Serine/threonine-protein kinase mTOR inhibitor; PI3-kinase class I inhibitor
MTOR, PIK3R1, PIK3CB, PIK3CG, PIK3CAPhase 2Respiratory Tract Infections; Covid19–
Eli LillySamotolisib (LY3023414)
Serine/threonine-protein kinase mTOR inhibitor; PI3-kinase class I inhibitor
MTOR, PIK3R1, PIK3CB, PIK3CG, PIK3CAPhase 1Breast Neoplasms; Endometrial CancerDec 2026
SovargenPaxalisib (SVG103)
PI3-kinase class I inhibitor
PIK3R1, PIK3CB, PIK3CG, PIK3CA, PIK3R2Phase 1Focal Cortical Dysplasia; Primary Central Nervous System Lymphoma; Glioblastoma; CDK Gene Mutation …Feb 2027

Conditions

Breast Cancer (2) Endometrial Cancer (2) Respiratory Tract Infections (1) Covid19 (1) mCRPC (Metastatic Castration-resistant Prostate Cancer) (1) TNBC - Triple-Negative Breast Cancer (1) Advanced Lymphoma (1) Breast Neoplasms (1) Focal Cortical Dysplasia (1) Primary Central Nervous System Lymphoma (1) Glioblastoma (1) CDK Gene Mutation (1)

Modalities

small molecule (4), mixed (1)

Companies

Restorbio (1) Celcuity (1) National Cancer Institute (NCI) (1) Eli Lilly (1) Sovargen (1)

Related targets

PIK3CB (5) PIK3CG (5) PIK3CA (5) MTOR (3) PIK3R2 (2)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.